Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 4
2013 2
2014 3
2015 3
2016 7
2017 4
2018 4
2019 7
2020 6
2021 11
2022 12
2023 3
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Among authors: kuhnen p. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
Pharmacotherapy in Childhood Obesity.
Kühnen P, Biebermann H, Wiegand S. Kühnen P, et al. Horm Res Paediatr. 2022;95(2):177-192. doi: 10.1159/000518432. Epub 2021 Jul 19. Horm Res Paediatr. 2022. PMID: 34351307 Review.
Hypothalamic obesity: from basic mechanisms to clinical perspectives.
Argente J, Farooqi IS, Chowen JA, Kühnen P, López M, Morselli E, Gan HW, Spoudeas HA, Wabitsch M, Tena-Sempere M. Argente J, et al. Among authors: kuhnen p. Lancet Diabetes Endocrinol. 2025 Jan;13(1):57-68. doi: 10.1016/S2213-8587(24)00283-3. Epub 2024 Nov 12. Lancet Diabetes Endocrinol. 2025. PMID: 39547253 Review.
IMPROVE 2022 International Meeting on Pathway-Related Obesity: Vision of Excellence.
Kühnen P, Argente J, Clément K, Dollfus H, Dubern B, Farooqi S, de Groot C, Grüters A, Holm JC, Hopkins M, Kleinendorst L, Körner A, Meeker D, Rydén M, von Schnurbein J, Tschöp M, Yeo GSH, Zorn S, Wabitsch M. Kühnen P, et al. Clin Obes. 2024 Jun;14(3):e12659. doi: 10.1111/cob.12659. Epub 2024 Apr 11. Clin Obes. 2024. PMID: 38602039
Melanocortin 4 receptor mutations become common.
Kühnen P, Biebermann H, Krude H. Kühnen P, et al. Cell Metab. 2021 Aug 3;33(8):1512-1513. doi: 10.1016/j.cmet.2021.07.003. Cell Metab. 2021. PMID: 34348096 Free article.
Pharmacological treatment strategies for patients with monogenic obesity.
Kühnen P, Wiegand S, Biebermann H. Kühnen P, et al. J Pediatr Endocrinol Metab. 2020 Jul 3:/j/jpem.ahead-of-print/jpem-2020-0129/jpem-2020-0129.xml. doi: 10.1515/jpem-2020-0129. Online ahead of print. J Pediatr Endocrinol Metab. 2020. PMID: 32619193 Review.
Generation of iPSC lines with SLC16A2:G401R or SLC16A2 knock out.
Ludwik KA, Opitz R, Jyrch S, Megges M, Weiner J, Beule D, Kühnen P, Stachelscheid H. Ludwik KA, et al. Among authors: kuhnen p. Stem Cell Res. 2023 Dec;73:103256. doi: 10.1016/j.scr.2023.103256. Epub 2023 Nov 21. Stem Cell Res. 2023. PMID: 38006677 Free article.
66 results